Expanded Access Policy

Braveheart Bio is focused on developing precision therapies for cardiovascular disease. We believe the best way to understand the potential of our investigational candidate, BHB-1893, is to study its efficacy and safety in late-stage clinical development. While we recognize there may be potential interest in accessing BHB-1893 outside of formal clinical trials, we do not offer expanded access to BHB-1893 at this time. Currently, our efforts are focused on advancing its clinical development to obtain regulatory approvals to make it available to appropriate patients as soon as possible. Should our policy on expanded access change in the future, we will post an updated policy here. If you are a health care provider who is interested in learning more about our investigational therapy, or a physician, patient or caregiver with questions about participation in one of our clinical trials, please submit a request to info@braveheart.bio.

Braveheart Bio will acknowledge inquiries as soon as possible, usually within 5 business days of receipt. For a list of our current ongoing clinical trials, visit www.ClinicalTrials.gov.